NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00152230,A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC),https://clinicaltrials.gov/study/NCT00152230,,COMPLETED,"This is a controlled study designed to compare relapse-free survival and overall survival in patients receiving UFT with those in patients receiving surgery alone. Patients will be randomly assigned to surgery alone or surgery followed by UFT within 6 weeks after curative resection. To assess treatment efficacy, data on recurrence and survival will be collected for 5 years after enrollment of the last patient. To evaluate safety, data on adverse events will be collected for 12 months after the start of treatment.Evaluations will be separately done for colon cancer and rectal cancer.",NO,Colorectal Cancer,"DRUG: UFT (uracil, tegafur)|PROCEDURE: Surgery alone","Relapse-free survival and overall survival, every course for first three courses, then every other course","Adverse events, any time",,"Taiho Pharmaceutical Co., Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,900,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,01023002,1996-10,2006-03,2008-02,2005-09-09,,2011-07-07,"National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, Japan",
